MedPath

Effect of 60-days Saccharomyces Boulardii and Superoxide Dismutase Supplementation in Obese Adults

Not Applicable
Completed
Conditions
Superoxide Dismutase
Obesity
Interventions
Dietary Supplement: Saccharomyces boulardii and SOD
Combination Product: Placebo
Registration Number
NCT04919850
Lead Sponsor
Azienda di Servizi alla Persona di Pavia
Brief Summary

In animals it has been demonstrated that Saccharomyces boulardii decrease low-grade inflammation and fat mass; also Superoxide Dismutase (SOD) decrease low-grade inflammation. Therefore, the aim of this double-blind, placebo-controlled clinical trial was to assess the effect of a 60-days S. boulardii and SOD supplementation on circulating markers of inflammation, body composition, hunger sensation, pro/antioxidant ratio, hormonal, lipid profile, glucose, insulin and HOMA-IR, in obese adults (BMI 30-35 kg/m2).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
25
Inclusion Criteria
  • I class of obesity (BMI: 30-35 Kg/m2)
Exclusion Criteria
  • evidence of heart, kidney or liver disease
  • diagnosis of major depressive disorder
  • current medications for weight loss, for control of cholesterol and triglycerides
  • anti-inflammatory treatments
  • pregrancy of lactation
  • type 1 diabetes mellitus, intestinal inflammatory bowel disease, celiac disease, chronic pancreatitis
  • probiotic/prebiotic treatment in the last 4 weeks
  • antibiotic use within the last 3 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention groupSaccharomyces boulardii and SODA complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes
Placebo groupPlaceboA placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
Primary Outcome Measures
NameTimeMethod
Change on concentration of biochemical parameters for hunger sensation and hormonal statusChanges from baseline biochemical parameters for hunger sensation and hormonal status at 8 weeks

glucagon-like peptide - 1 (pmol/L)

Change on concentration of biochemical parameters for glico-metabolic statusChanges from baseline biochemical parameters for glico-metabolic status at 8 weeks

HOMA index (pt)

Change on state of hunger, fullness, desire to eat, satiety and prospective food consumptionChanges from baseline state of hunger, fullness, desire to eat, satiety and prospective food consumption at 8 weeks

Eating motivation Visual Analogue Scale (pt): a scale from 0 to 10 points. The scale of hunger (question: "how hungry are you?") ranged from the answer "not at all" to "as hungry as I have ever felt"; the scale of fullness (question: "how full are you?") ranged from the answer "not at all" to "as full as I ever felt"; the scale of satiety (question: "how satiated are you?") ranged from "not at all" to "extremely"; the scale of desire (question: "how strong is your desire to eat?") ranged from "very weak" to "very strong"; the scale of prospective consumption (question: "how much do you think you could (or would want to) eat right now) ranged from "nothing at all" to "a very large amount"

Secondary Outcome Measures
NameTimeMethod
Change on concentration of biochemical parameters for hormonal statusChanges from baseline biochemical parameters for hormonal status at 8 weeks

Thyroid Stimulating Hormone (µU/dL)

Change on concentration of biochemical parameters for inflammation and cardiovascular riskChanges from baseline biochemical parameters for inflammation and cardiovascular risk at 8 weeks

Trimethylamine (µM), Trimethylamine-N-oxide (µM)

Change on concentration of biochemical parameters for safetyChanges from baseline biochemical parameters for safety at 8 weeks

Creatinine (mg/dl)

Change on status of mood assessmentChanges from baseline mood assessment at 8 weeks

Beck questionnaire (pt). The questionnaire is divided into 21 items which have a score from 0 to 3. A total score \> 17 indicates borderline depression; \> 21 moderate depression; \> 31 severe depression; \> 40 extreme depression.

Change on status of assessment of food preferencesChanges from baseline assessment of food preferences at 8 weeks

Food Frequency Questionnaire (pt). Participants must indicate the consumption of 18 common food items, choosing one between "yes" or "no, never". Participants were also asked to estimate their usual rate of consumption, choosing from seven categories of frequency, ranging from ''never'' or ''less than once a week'' to ''seven times per week". The only exception was constituted by the item "coffee consumption", which is reported as "cups/day".

Change on concentration of biochemical parameters for nutritional statusChanges from baseline biochemical parameters for nutritional status at 8 weeks

Iron (µg/dL)

Change on rate of anthropometric measuresChanges from baseline anthropometric measures at 8 weeks

Body mass index (kg/m2)

Change on rate of body compositionChanges from baseline body composition at 8 weeks

Visceral Adipose Tissue (g)

Trial Locations

Locations (1)

Azienda di Servizi alla Persona

🇮🇹

Pavia, Italy

© Copyright 2025. All Rights Reserved by MedPath